No Data
No Data
Zhejiang Anglikang Pharmaceutical (002940.SZ): Has repurchased a total of 1.78% of its shares.
On May 6, Gelonhui reported that Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that as of April 30, 2025, the company had repurchased a total of 3,599,500 shares through a special securities repurchase account via centralized bidding, accounting for approximately 1.78% of the company's total share capital, with a highest Fill Price of 14.87 yuan per share, a lowest Fill Price of 12.17 yuan per share, and a total trade amount of 49,997,875.28 yuan (excluding transaction costs).
Onlikon: Report for the first quarter of 2025
Express News | Zhejiang Anglikang Pharmaceutical: The application for the marketing of the chemical raw materials for Domperidone has been approved.
Zhejiang Anglikang Pharmaceutical (002940.SZ): The Innovative Drugs injection ALK-N001 has received the Clinical Trial Approval Notification.
Gelonghui, April 27 - Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that recently, Zhejiang Anglikang Pharmaceutical Co., Ltd. received the approval notice for the clinical trial of the injectable ALK-N001 issued by the National Medical Products Administration. Preclinical research results show that injectable ALK-N001 can dose-dependently inhibit tumor growth in HT1080 (human fibrosarcoma) and CT26 (mouse colon cancer) models. Compared with DXD treatment, ALK-N001 has a stronger anti-tumor effect at equivalent molar doses or low molar doses, with its final tumor suppression rate.
Express News | Zhejiang Anglikang Pharmaceutical: The injectable Innovative Drug ALK-N001 has received the notice of approval for clinical trials.
Onlikon: 2024 Annual Report